Cerecor Inc.: directors' dealings · United States · SEC (Form 4)

About Cerecor Inc.

Cerecor Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ Capital Market under the ticker CERC. The company is based in the United States and has historically operated from Rockville, Maryland. Cerecor was founded in 2011 and went public in 2015. Its strategic direction has since been reshaped by the February 2020 merger with Aevi Genomic Medicine, which broadened the pipeline and added leadership focused on rare-disease drug development, immunology and oncology programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1534120/000162828021004162/cerc-20201231.htm)) Cerecor’s business model is centered on research and development rather than a broad commercial franchise. The company has pursued a portfolio of clinical-stage assets aimed at rare and orphan diseases, with a particular emphasis on pediatric unmet need. Key programs described in SEC filings include the CERC-800 series (CERC-801, CERC-802 and CERC-803) for congenital disorders of glycosylation, CERC-006, an oral mTORC1/2 inhibitor being developed for complex lymphatic malformations, and two monoclonal antibodies, CERC-002 and CERC-007, targeting inflammatory and oncology-related pathways. Several of these candidates have received Orphan Drug Designation and Rare Pediatric Disease Designation, which can be strategically meaningful in rare-disease drug development if clinical and regulatory execution is successful. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1534120/000162828021004162/cerc-20201231.htm)) From a competitive standpoint, Cerecor fits the profile of a niche specialty biotech, competing on scientific differentiation, regulatory optionality and capital efficiency rather than scale. Its potential value proposition lies in targeting highly specific patient populations with limited treatment options, where a successful program can create outsized commercial or partnering value. At the same time, the investment case remains high risk: the company has a history of material losses, relies on external financing, and continues to face the binary outcomes typical of clinical-stage biotech development. Cerecor has also indicated that it continues to evaluate strategic alternatives for non-core assets, including Millipred, its commercialized oral prednisolone product. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1534120/000162828021004162/cerc-20201231.htm)) Geographically, Cerecor’s operational footprint is primarily U.S.-based, with administrative and development activities anchored in Maryland. In June 2021, the company disclosed a $35 million venture debt facility intended to support working capital, pipeline development and general corporate purposes, underscoring the capital-intensive nature of its business. Recent company updates relevant to investors include ongoing development of its rare-disease assets and market disclosures through SEC filings, including Form 4 insider transactions that may help investors track management and insider sentiment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1534120/000162828021011771/cerc-20210604.htm?utm_source=openai))